EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Merck’s first attempt covered the use of Keytruda across six cancer types – melanoma, Hodgkin’s lymphoma ... in the market over arch-rival Opdivo (nivolumab) from Bristol-Myers Squibb ...
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...
Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...
Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Y., et al.) demonstrates that the addition of CAN-2409 and nivolumab and standard of care was generally well tolerated and extended survival in a subset of patients with evidence of local and ...
Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage classical Hodgkin lymphoma, making it an option for around 800 people ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback